glp 1 mind body GLP-1 for Weight Loss and Diabetes GLP-1 Support (Energy Focus) –

A report from the EMAs PRAC, published on 12 April 2024, said: After reviewing the available evidence from non-clinical studies, clinical trials, post-marketing surveillance data and the available studies the PRAC considers that no update to the product information is warranted. The PRAC statement said that market authorisation holders would continue to monitor events, including new studies, as part of their pharmacovigilance activities

doi: 10.1155/2018/1752940 269 ViktorinovaAJurkovicovaIFabryovaLKinovaSKorenMStecovaAet al

Doesnt hurt, just feels weird

First, while the rescue experiments with ferric citrate and NAC strongly support an iron deficiency and ROS-mediated mechanism, the absence of established positive controls, such as the iron chelator deferoxamine (DFO) or direct ROS generators, precludes a definitive comparative conclusion that the observed effects are uniquely attributable to CGAs iron-chelating activity

Per a March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products, including claims implying sameness with FDA-approved medications